论文信息 - Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.

Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.

From Monoclonal Antibodies for C. difficile Therapy II, no participants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab infusion experienced recurrent Clostridioides difficile infection (rCDI) after 9 months (versus actoxumab + bezlotoxumab, n = 2/65; versus placebo, n = 1/34). Bezlotoxumab's efficacy appears to be due to prevention rather than delayed onset of rCDI. CLINICAL TRIALS REGISTRATION NCT01513239.

[1] K. Garey,et al. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection , 2018, Antimicrobial Agents and Chemotherapy.

[2] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection , 2017, The New England journal of medicine.

[3] A. Therien,et al. Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling , 2014, Antimicrobial Agents and Chemotherapy.

[4] E. Kuijper,et al. Humoral immune response as predictor of recurrence in Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5] C. Kelly,et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.